Cargando…

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer

BACKGROUND: Endo180 (CD280; MRC2; uPARAP)-dependent collagen remodelling is dysregulated in primary tumours and bone metastasis. Here, we confirm the release and diagnostic accuracy of soluble Endo180 for diagnosing metastasis in breast cancer (BCa). METHODS: Endo180 was quantified in BCa cell condi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmieri, C, Caley, M P, Purshouse, K, Fonseca, A-V, Rodriguez-Teja, M, Kogianni, G, Woodley, L, Odendaal, J, Elliott, K, Waxman, J, Sturge, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553530/ https://www.ncbi.nlm.nih.gov/pubmed/23257899 http://dx.doi.org/10.1038/bjc.2012.540

Ejemplares similares

Tumor-associated Endo180 requires stromal-derived LOX to promote metastatic prostate cancer cell migration on human ECM surfaces
por: Caley, Matthew P., et al.
Publicado: (2015)

Endo180 at the cutting edge of bone cancer treatment and beyond
por: Sturge, Justin
Publicado: (2016)

Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection
por: Nunes, J, et al.
Publicado: (2012)

GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis
por: Sturge, Justin, et al.
Publicado: (2003)

Endosomes generate localized Rho–ROCK–MLC2–based contractile signals via Endo180 to promote adhesion disassembly
por: Sturge, Justin, et al.
Publicado: (2006)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma
por: Matsuoka, T, et al.
Publicado: (2012)

Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer
por: Kawano, Y, et al.
Publicado: (2009)

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
por: Dotan, E, et al.
Publicado: (2012)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer
por: Kim, J C, et al.
Publicado: (2013)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma
por: Jeppesen, A N, et al.
Publicado: (2010)

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215
por: White, N M A, et al.
Publicado: (2011)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Annexin II represents metastatic potential in clear-cell renal cell carcinoma
por: Ohno, Y, et al.
Publicado: (2009)

HIF-1α determines the metastatic potential of gastric cancer cells
por: Rohwer, N, et al.
Publicado: (2009)

Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer
por: Murata, A, et al.
Publicado: (2013)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells
por: Ueno, K, et al.
Publicado: (2009)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma
por: Maruyama, R, et al.
Publicado: (2006)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
por: Wang, H, et al.
Publicado: (2012)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

The differential effects of statins on the metastatic behaviour of prostate cancer
por: Brown, M, et al.
Publicado: (2012)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial–mesenchymal transition in metastatic nasopharyngeal carcinoma
por: Horikawa, T, et al.
Publicado: (2011)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β(3) affinity modulation
por: Goc, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_aogrok08ta2n0vihlk4pspa68c